Multi-link Vision and MiniVision stent registry in Asian patients with coronary artery disease: a prospective, multi-center study

Outcome of patients treated by a novel thin‐strut cobalt‐chromium stent in the drug‐eluting stent era: Results of the SKICE (Skylor in real world practice) registry

“…In conclusion, this study suggests that patients with limited compliance to prolonged double antiplatelet therapy, STEMI, or noncomplex angiographic lesions undergoing implantation of the investigated stent may have clinical outcome, which is comparable with that reported in recent registries with different design using other last generation BMS [15–20].…”

“…On the other hand, the need of DES instead of new generation BMS in the cases at lower risk of restenosis has been challenged by a recent sub‐study showing no advantage of sirolimus‐eluting stent compared to a thin‐strut BMS in larger vessels (RVD > 2.8 mm) [14]. Eventually, the clinical results observed in our registry with the Skylor™ stent appear to be comparable with those reported in recent registries with other last generation BMSs [15–20] and also with those reported in a previous Skylor™ stent registry (Table V) [21].…”

Effect on Clinical Restenosis of an Ultra‐Thin‐Strut Bare Metal Cobalt‐Chromium Stent Versus a Thin‐Strut Stainless Steel Stent

“…In registry studies, the TLR‐rate for the Driver stent in 298 selected patients was 8.8% after 9 months . For the Vision stent, TLR after 6 months was 7.8% …”

“…Thinner strut cobalt‐chromium (Cro‐Co) BMS has advantages over stainless steel (SS) BMS in terms of significant reduction of neointimal formation, increased flexibility, and better deliverability without compromising radial strength or radio‐opacity. This has resulted in a significant reduction of neointimal formation and subsequent target‐lesion revascularization (TLR) compared with SS BMS . The aim of this study is to compare in real world practice a 65 μm Cro‐Co ultra‐thin strut stent versus an 80 μm SS thin‐strut stent in order to assess whether a reduced strut thickness is associated with less TLR.…”

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)

“…The performance of the Multi-Link Vision has already been proved in clinical practice, and this stent is among the most commonly used worldwide (Kaiser et al 2005; Ortolani et al 2007; Xu et al 2007). …”